Published on
May 30, 2025
As Austedo, Ajovy and Uzedy gain steam, Teva banks on $5B-plus in 2030 innovative drug sales
From five years of sales declines to nine consecutive quarters of growth, it’s hard to deny that Teva’s revamp under CEO Richard Francis is paying off. Now, following the completion of the strategy’s first phase—which focused on restoring the company to …
Source:
Fierce Pharma
-
Neutral
